Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2026)
Gyre Therapeutics (GYRE) recorded Income from Non-Controlling Interests of -$3.67 million in Q2 2026, compared with -$2.84 million a year earlier.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
On a TTM basis, Gyre Therapeutics' Income from Non-Controlling Interests came in at -$2.15 million as of Jun 30, 2026; for FY2025, it was $4.85 million, down 16.5% from FY2024.
- Annual Income from Non-Controlling Interests has a three-year compound annual growth rate of 34.1% (FY2022 to FY2025).
- Across earlier years, Income from Non-Controlling Interests came in at $5.81 million in FY2024 (-22.0%), $7.45 million in FY2023 (+270.4%) and $2.01 million in FY2022.
- The Q2 2026 figure is the lowest quarterly Income from Non-Controlling Interests in data going back to Q1 2023.
- On a year-over-year basis, Income from Non-Controlling Interests rose in 1 of the last four quarters, with an average decline of 30.0%.
- Per Business Quant, the preceding three quarters came in at -$1.17 million (Q1 2026), $357,000 (Q4 2025) and $2.33 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | - |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | - |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.00 Mn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -2.00 Mn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | -7.00 Mn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 1.00 Mn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | - |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | - |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 10.00 Mn |
| 10 | Gyre Therapeutics | 753.90 Mn | 556.61 Mn | 26.90 Mn | -3.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.67 Mn |
| Mar 31, 2026 | -1.17 Mn |
| Dec 31, 2025 | 357,000.00 |
| Sep 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | -2.84 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 668,000.00 |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 29,000.00 |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.97 Mn |
API Access
Gyre Therapeutics Income from Non-Controlling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=GYRE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "GYRE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=GYRE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();